Literature DB >> 15301302

Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy.

G Cadario1, F Marengo, E Ranghino, R Rossi, B Gatti, R Cantone, F Bona, R Pellegrino, G Feyles, P Puccinelli, S E Burastero.   

Abstract

Venom immunotherapy has proven a very effective method for the treatment of allergy to Hymenoptera venom. Aqueous instead of depot extracts are prevalently used for this immunotherapy. The advantage of using aqueous extracts has not been fully investigated. We made an open, non-controlled study on 45 subjects sensitized to either Apis mellifera or Vespula spp. Patients were assigned to either a depot (N=27) or an aqueous (N=18) immunotherapy regimen, and side effects were monitored during the induction and the 3-year maintenance phase. The effect of naturally occurring stings during the treatment and after its interruption was recorded as well. Side effects were less frequent with the depot extract both on a "per patient" (22.2% versus 50.0%) and on a "per dose" (2.9% versus 10,2%) basis (p=0.026 and p<0.000, respectively). Better tolerance was mainly due to the lower frequency of local side effects occurring at early times after vaccination. The efficacy of vaccination was comparable in the 2 cohorts, as expected. We conclude that depot immunotherapy to Hymenoptera venom should be preferred to aqueous immunotherapy for the lower occurrence of local side effects. This might influence a better compliance with this potentially life-saving treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301302

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  4 in total

1.  Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional Protocol.

Authors:  Vincenzo Patella; Giovanni Florio; Ada Giuliano; Carmine Oricchio; Giuseppe Spadaro; Gianni Marone; Arturo Genovese
Journal:  J Allergy (Cairo)       Date:  2012-05-24

Review 2.  Risk associated with bee venom therapy: a systematic review and meta-analysis.

Authors:  Jeong Hwan Park; Bo Kyung Yim; Jun-Hwan Lee; Sanghun Lee; Tae-Hun Kim
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

3.  Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy.

Authors:  Robert Heddle; Anthony Smith; Richard Woodman; Pravin Hissaria; Nikolai Petrovsky
Journal:  J Allergy Clin Immunol       Date:  2019-07-09       Impact factor: 10.793

4.  Safety and tolerability of venom immunotherapy: Evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy).

Authors:  Richard Stock; Tatjana Fischer; Katharina Aẞmus; Nadja Zoeller; Hanns Ackermann; Roland Kaufmann; Markus Meissner; Eva Valesky
Journal:  World Allergy Organ J       Date:  2020-12-15       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.